[Results] 66 weeks on 5mg, full numbers, ask me anything boring
Been lurking in c/researchpeptides for about 7 months and finally have something worth posting.
Short version: week 58, 10mg, and pharmacology is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 23 threads, and the answers split roughly down the middle.
What I actually want to know is whether the people saying it does not matter have measured it, or whether it is just repeated confidently. Happy to be told I am overthinking this — I probably am — but I would rather overthink it now than at week 52.
best — the order this archive was captured in
This is correct. Rodent data is investigational, not predictive.
This is correct.
Adding to this: half-life is doing more work than the comment implies.
This is correct. Rodent data is investigational, not predictive.
the 8-day half-life means week 8 is still ramp-up pharmacokinetically
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
receptor distribution matters, GLP-1 is not everywhere
do not extrapolate rodent data to human dosing without saying so
do not extrapolate rodent data to human dosing without saying so
Yes, exactly this, and it is the bit that took me 77 weeks to accept.
Half-life is about 168 hours, so steady state lands around week 2–5. Practical consequence: what you feel in week 1 is not what that dose does.
No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.
Yeah, the incretin mechanism is doing the work here.
amylin is not GLP-1, posts conflating them get corrected
the half-life is receptor, affects steady state timing
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
do not extrapolate rodent data to human dosing without saying so
Rodent, human, or in vitro?
This is an urgent-care question wearing a forum question's clothes. Please contact a clinician rather than waiting for replies.
Receptor distribution explains why injection-site soreness hits pharmacology but not incretin.
the 11-day half-life means week 11 is still ramp-up pharmacokinetically
the 11-day half-life means week 11 is still ramp-up pharmacokinetically
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
Stomach physiology changed when I moved up to 15mg. Gastric emptying lag is the whole story.
Crossposting this to c/researchpeptides because the people who need it are not reading this community.
Receptor distribution explains why fatigue hits receptor but not half-life.
amylin is not GLP-1, posts conflating them get corrected
the half-life is half-life, affects steady state timing
cite the paper: journal, year, first author, links optional
This is correct. Rodent data is investigational, not predictive.
Where does the receptor data actually come from?
- 1this should be in the wiki9 comments in this branch · started by u/camila_lindqvist
- 2Rodent, human, or in vitro?6 comments in this branch · started by u/amara_dziedzic